# Panel — CA-14 (Phase B HARD gate + Self-Renewal invariants + findings-driven + per-product branch + atomic-audit-write) — quorum-fix rerun (2026-05-19)

**Bundle:** 34212 chars (target ≤~30K to match proven 27,778-char recipe)
**Started:** 2026-05-19T04:28:53.478Z · **Finished:** 2026-05-19T04:30:49.892Z
**Engaged:** 10/10 · **Tangential:** 0 · **Silent:** 0
**Distinct objections:** 36
**Alignment:** 64.5% · ✅ PASS

## Per-question
| Q | Verdict | Top key | Top / Engaged | Cleared (drafted ≥7) |
|---|---|---|---|---|
| **CA-14-A-Q1** | `PLURALITY_CA14AQ1-OPTIN` | `CA14AQ1-OPTIN` | 4/10 | — |
| **CA-14-A-Q2** | `QUORUM_PLURALITY_CA14AQ2-RATIFY` | `CA14AQ2-RATIFY` | 7/10 | ✅ |
| **CA-14-A-Q3** | `SUPERMAJORITY_CA14AQ3-AGENT21` | `CA14AQ3-AGENT21` | 8/10 | ✅ |
| **CA-14-A-Q4** | `SUPERMAJORITY_CA14AQ4-RATIFY` | `CA14AQ4-RATIFY` | 8/10 | ✅ |
| **CA-14-B-Q1** | `QUORUM_PLURALITY_CA14BQ1-RATIFY` | `CA14BQ1-RATIFY` | 7/10 | ✅ |
| **CA-14-B-Q2** | `QUORUM_PLURALITY_CA14BQ2-RATIFY` | `CA14BQ2-RATIFY` | 7/10 | ✅ |
| **CA-14-B-Q3** | `PLURALITY_CA14BQ3-RATIFY` | `CA14BQ3-RATIFY` | 6/10 | — |
| **CA-14-C-Q1** | `PLURALITY_CA14CQ1-RATIFY` | `CA14CQ1-RATIFY` | 6/10 | — |
| **CA-14-C-Q2** | `PLURALITY_CA14CQ2-ADD` | `CA14CQ2-ADD` | 6/10 | — |
| **CA-14-D-Q1** | `SUPERMAJORITY_CA14DQ1-RATIFY` | `CA14DQ1-RATIFY` | 8/10 | ✅ |
| **CA-14-D-Q2** | `PLURALITY_CA14DQ2-NDAYS` | `CA14DQ2-NDAYS` | 6/10 | — |

## All distinct objections (36)
**01. [Slot 1] Phase B scope creep without bounds**

> §6.10 Phase B defines adversarial testing including 'prompt-injection probes' and 'hostile input' but provides no upper bound on test complexity or time. Unlike Phase A's hard caps (depth=12, pages=2000), Phase B could expand indefinitely as new attack vectors emerge.

**02. [Slot 1] Atomic-audit-write creates deadlock risk**

> §7.5 requires ProductSSOT update to be atomic with output delivery - if ProductSSOT write fails, entire run rolls back. This creates a single point of failure where database contention or network issues could block all product renewals system-wide.

**03. [Slot 1] NO_IMPROVEMENT exit blocks valid fixes**

> §7 item #6d mandates rejecting any fix that causes score regression, but some legitimate fixes (security patches, removing vulnerable features) naturally reduce functionality scores. The 'never ships regression' guarantee prevents necessary security remediation.

**04. [Slot 1] Per-product branch proliferation unbounded**

> CA-14-D requires a branch-of-record per product but doesn't specify retention policy or cleanup. With continuous operation, this creates unbounded git repository growth as abandoned product branches accumulate indefinitely.

**05. [Slot 2] Phase B complexity and resource demand**

> The introduction of Phase B Adversarial Surface Testing as a hard prerequisite (§6.10) significantly increases the complexity and resource demand of the testing process. This could lead to delays in product releases and increased operational costs, especially for smaller teams or projects with limited resources.

**06. [Slot 2] Lack of rollback mechanism**

> The proposal does not specify a clear rollback mechanism if Phase B testing fails after a product has been partially deployed. This could result in incomplete or inconsistent product states, potentially affecting end-user experience and trust.

**07. [Slot 2] Potential for increased false negatives**

> The adversarial testing approach in Phase B may lead to increased false negatives, where legitimate product features are flagged as problematic due to overly aggressive testing scenarios. This could hinder the deployment of functional products and require unnecessary remediation efforts.

**08. [Slot 3] Lack of Rollback**

> The proposal does not provide a clear rollback strategy in case the Phase B Adversarial Surface Testing introduces unintended consequences or regressions, which could lead to system instability.

**09. [Slot 3] Insufficient Error Handling**

> The §7.6 GTM Readiness Report score does not account for error handling and recovery mechanisms, which are crucial for ensuring system reliability and robustness.

**10. [Slot 3] Overreliance on Automated Testing**

> The proposal relies heavily on automated testing, which may not cover all edge cases and scenarios, potentially leading to undetected issues and vulnerabilities.

**11. [Slot 4] Phase B Overhead**

> The introduction of Phase B Adversarial Surface Testing may significantly increase the time and resources required for testing, potentially delaying product releases and increasing costs. §6.10 outlines extensive interactive testing requirements that could be overly burdensome.

**12. [Slot 4] Complexity in Self-Renewal**

> The Self-Renewal safety invariants in §7 Output Contract add complexity to the fix generation process. The diff-only and preserve rules might limit the effectiveness of automated fixes, leading to more manual interventions. The pre-deploy parse gate and post-deploy regression guard could introduce additional failure points.

**13. [Slot 4] Incomplete Seeding**

> The per-product seed migration in §7.5.1 is incomplete, with only 2 out of 5 VEU products seeded. This could lead to inconsistencies and potential issues in the ProductSSOT rows, affecting the reliability of the system.

**14. [Slot 5] Complexity Increase**

> Adding Phase B Adversarial Surface Testing as a hard prerequisite significantly increases the complexity of the clearance process, potentially leading to delays and resource strain.

**15. [Slot 5] Resource Allocation**

> The additional testing phase may require more computational resources and human oversight, which could divert resources from other critical areas.

**16. [Slot 5] False Positives**

> Phase B testing may generate false positives, leading to unnecessary rework and potential frustration among developers.

**17. [Slot 6] Phase B scope creep**

> The definition of Phase B in §6.10 is broad and could lead to scope creep.  The lack of specific, measurable criteria for 'adversarial' testing makes it difficult to determine when Phase B is truly 'passed'. This ambiguity could lead to inconsistent application and disputes.

**18. [Slot 6] LIMITATIONS disclosure burden**

> The mandatory verbatim text in §7 LIMITATIONS places a significant burden on operators.  While the intent is good, requiring exact phrasing is inflexible and could lead to awkward or unnatural disclosures.  The system should allow for paraphrasing while maintaining the core intent.

**19. [Slot 6] Self-Renewal safety rigidity**

> The §7 Output Contract item #6, particularly the 'diff-only' and 'preserve rules' invariants, may be overly restrictive.  Legitimate fixes might require more substantial changes than a simple diff, and preserving all existing code (including potentially flawed code) could hinder effective remediation.

**20. [Slot 6] Five-Layer Framework demotion**

> CA-14-C's demotion of the Five-Layer Intelligence Framework to telemetry-only seems premature. While findings-driven prioritization is important, the Five-Layer Framework could provide valuable context for understanding the business impact of different findings, potentially leading to more strategic remediation efforts.  The proposal doesn't adequately justify this shift.

**21. [Slot 6] ProductSSOT seeding risk**

> The per-product branch-of-record and ProductSSOT row seeding in CA-14-D introduce a risk of data inconsistencies if the seeding process is not carefully managed.  Seeding only two products (FlowAI + MyPregLife) while leaving the remaining four pending creates a potential for divergence and confusion.

**22. [Slot 7] Phase B scalability risk**

> CA-14-A §6.10 mandates comprehensive authenticated traversal and adversarial probing without defining resource constraints. The requirement to exercise every authenticated multi-page path and perform adversarial prompt injection on all AI agents could exponentially increase crawl time and compute costs beyond Phase A's hard caps, potentially stalling pipeline throughput.

**23. [Slot 7] Regression guard false positives**

> CA-14-B §7 item #6(d) mandates rejecting any fix causing §7.6 score regression. However, §7.6 scores fluctuate due to environmental factors (e.g., third-party API latency). This could cause valid fixes to be rejected for non-regression reasons, worsening Cluster D deferred issue backlog.

**24. [Slot 7] Atomic-write contention risk**

> CA-14-D §7.5.1 requires atomic ProductSSOT writes across environments. During concurrent pipeline runs for the same product, write contention could trigger rollbacks and incomplete runs, violating §7 Output Contract completeness guarantees and creating version skew.

**25. [Slot 7] Phase B opt-in expansion hazard**

> CA-14-A §6.10 expands XSS probe opt-in to dev/staging environments during Phase B. Without strict session isolation, adversarial payloads like <script>alert(1)</script> could contaminate test data stores and cause downstream data corruption in shared environments.

**26. [Slot 8] Phase B gate is underspecified**

> CA-14-A amends §7.6 and §11 Step 5 to require a Phase B adversarial pass, but it does not define a measurable pass/fail rubric for the new `phase_b_pass` boolean beyond “zero critical” and some high-finding handling. Without a canonical scoring contract, operators can satisfy the gate with inconsistent ad hoc test coverage while still presenting the result as a hard certification.

**27. [Slot 8] LIMITATIONS disclosure is brittle**

> The new §7 LIMITATIONS wording mandates a verbatim disclaimer for Phase A-only deliveries and forbids paraphrase. That creates a compliance footgun: any downstream formatting, localization, or report-generation layer that slightly alters the phrase turns a valid delivery into a canonical violation even if the substantive disclosure is present.

**28. [Slot 8] Safety invariants overreach into policy**

> CA-14-B elevates diff-only, preserve rules, parse gate, regression guard, and attribution into the SSOT as item #6 of §7 and as a Locked Rule extension. Several of these are implementation policies that belong in the remediation engine spec, not the canonical output contract; encoding them at SSOT level risks freezing tooling behavior that should remain evolvable.

**29. [Slot 8] Branch-of-record migration risk**

> CA-14-D requires per-product branch-of-record plus atomic-audit-write semantics across ProductSSOT seeding and audit logs, but the draft only names FlowAI and MyPregLife as already seeded while four other VEU products remain pending. Binding canonical behavior to partially migrated state can produce split-brain records where some products use the new branch model and others still rely on legacy paths.

**30. [Slot 8] Findings-driven priority may starve strategic work**

> CA-14-C makes §7.6 findings the source of truth for remediation and demotes the Five-Layer Framework to telemetry only. That can improve defect focus, but it also removes a structured mechanism for surfacing business, GTM, or financial risks that may not appear as high-severity technical findings yet still dominate product failure risk.

**31. [Slot 9] Overly Complex §6.10 Distinction**

> The new §6.10 distinction between Phase A and Phase B introduces additional complexity without clear benefits. It may lead to confusion among operators and developers.

**32. [Slot 9] Lack of Clear Ownership for Phase B**

> CA-14-A-Q3 does not clearly assign ownership for Phase B implementation, which may cause delays or confusion in the development process.

**33. [Slot 9] Insufficient Disclosure Requirements**

> The LIMITATIONS disclosure discipline introduced in CA-14-A may not be sufficient to ensure transparency, as it relies on operator compliance without clear enforcement mechanisms.

**34. [Slot 10] Phase B gate overloads §11 Step 5**

> The five-prerequisite gate added to §7.6 and §11 Step 5 (including new phase_b_pass boolean and skipped-paths enumeration) has no timeout, retry limit, or resource cap specified, unlike the depth=8/hard-cap=12 bounds already present in §6 Aggressive Crawl Engine; this can indefinitely block Clearance Step 5 for any product with complex authenticated flows.

**35. [Slot 10] Atomic ProductSSOT write lacks rollback**

> CA-14-D's atomic-audit-write requirement in §7.5 (tied to delta_log append and governance_record) combined with CA-14-B's post-deploy regression guard in new §7 item #6 can leave a ProductSSOT row in an inconsistent state if the guard triggers NO_IMPROVEMENT after a partial Self-Heal commit, with no explicit Self-Protect snapshot restore path named.

**36. [Slot 10] Findings-driven conflicts with §10 Self-Audit**

> CA-14-C's declaration that §7.6 findings are the sole remediation prioritizer (amending pipeline step 6) directly contradicts the five-dimension Self-Audit scoring engine in §10.1, which still feeds Platform Health Widget and triggers Self-Protection on sub-6 Security Posture without referencing findings as override.
